DURECT Corp

Aktienanalyse zu DURECT Corp (DRRX)

$1.910

-0.020 (-1.04%)Zum Schluss

Loading chart…
High
1.950
Open
1.930
VWAP
1.92
Vol
2.79M
Mkt Cap
42.37M
Low
1.910
Amount
5.36M
EV/EBITDA, TTM
0.00

DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has developed a proprietary drug product for the treatment of ADHD called Methydur.

www.durect.com

Analyst Ratings (3)

+30.89% upside
Hold
1 Buy
2 Hold
0 Sell
Current: 1.91
Tief
2.50
Durchschnitt
2.50
Hoch
2.50

Northland

2025-07-29

Kursziel

$2.50

Market Perform

HC Wainwright & Co.

2025-03-27

Kursziel

—

Hold

HC Wainwright & Co.

2024-11-14

Kursziel

—

Hold

HC Wainwright & Co.

2024-09-26

Kursziel

—

Hold

HC Wainwright & Co.

2024-05-22

Kursziel

—

Hold
See All Ratings

Bewertungskennzahlen

The current forward P/E ratio for DURECT Corp (DRRX) is -1.46, compared to its 5-year average forward P/E of -2.70.

Forward P/E

Fair
5Y Average P/E
-2.70
Current P/E
-1.46
Überbewertet
-0.95
Unterbewertet
-4.45

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward P/S

Strongly Overvalued
5Y Average P/S
10.13
Current P/S
33.36
Überbewertet
20.46
Unterbewertet
-0.19

Event-Zeitleiste

2025-08-26 (ET)

08:23:02

Bausch Health extends its tender offer for Durect.

2025-08-12 (ET)

16:33:53

Durect reports Q2 cont ops EPS (7c) vs. (13c) last year

2025-07-29 (ET)

07:18:54

Bausch Health to acquire Durect for $1.75 per share in cash upfront

07:02:53

Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction

2025-05-13 (ET)

16:09:50

Durect reports Q1 EPS (13c), consensus (12c)

Show More Events

News

Show More News

DRRX FAQ — answered by Alphio AI

DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has developed a proprietary drug product for the treatment of ADHD called Methydur. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

3 analysts cover DRRX: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 2.50.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten